In the industry's words
This article was originally published in RAJ Devices
On tenterhooks over the US Food and Drug Administration's reform of the 510(k) review process, the US medical technology industry is warning that the potential changes threaten its position as global leader in the supply of these products. Mark Leahey, president and CEO of the Medical Device Manufacturers Association, warns against any move that might lead to a major weakening of medtech innovation
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.